February 17, 2011
Cambridge, MA
Refresh your understanding of Federal Circuit case law in this program designed especially for IP lawyers practicing in biotechnology. Federal Circuit decisions can impact IP portfolio strategy on many levels and in significant or subtle ways. We have selected some decisions of particular importance that are worth a closer look.
Please join Finnegan attorneys Leslie A. McDonell and Amelia Feulner Baur, Ph.D., as they discuss the following biotechnology cases:
- Prometheus Laboratories Inc. v. Mayo Collaborative Services, et al.
- Method of treatment claims and 35 U.S.C. § 101
- Cancer Research Technology Ltd. v. Barr Laboratories, Inc.
- Prosecution latches and inequitable conduct
- Sun Pharmaceuticals Industries, Inc. v. Eli Lilly and Company
- Double patenting
Date:
Thursday, February 17, 2011
Time:
7:30 - 8:00 a.m.
Registration and Breakfast
8:00 - 9:00 a.m.
Program
Where:
Finnegan
55 Cambridge Parkway
Cambridge, MA
At the PTAB Blog
Federal Circuit PTAB Appeal Statistics for December 2023 and January 2024
March 8, 2024
Federal Circuit IP Blog
Prior Printed Publications “Publicly Available” Despite Confidentiality Restrictions
March 7, 2024
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in January 2024
March 7, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.